tetano
Editor, Senior Moderator
Biomed Pharmacother
. 2022 Apr 26;150:112997.
doi: 10.1016/j.biopha.2022.112997. Online ahead of print.
Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis
Peng Wang[SUP] 1 [/SUP], Jing Ni[SUP] 2 [/SUP], Ya-Ya Chu[SUP] 3 [/SUP], Qing-Qing Chen[SUP] 4 [/SUP], Guo-Cui Wu[SUP] 5 [/SUP], Yang Fang[SUP] 6 [/SUP], Cong Chen[SUP] 6 [/SUP], Ruo-Di Zhang[SUP] 6 [/SUP], Ling-Qiong Jiang[SUP] 6 [/SUP], Yan Zhao[SUP] 6 [/SUP], Xi Fang[SUP] 6 [/SUP], Jun He[SUP] 7 [/SUP], De-Guang Wang[SUP] 8 [/SUP], Gui-Hong Wang[SUP] 9 [/SUP], Hai-Feng Pan[SUP] 10 [/SUP]
Affiliations
Abstract
Background: This study aimed to investigate the seroreactivity of Coronavirus disease 2019 (COVID-19) vaccination and its adverse events among systemic lupus erythematosus (SLE) patients, rheumatoid arthritis (RA) patients, and healthy controls (HCs).
Methods: A total of 60 SLE patients, 70 RA patients and 35 HCs, who received a complete inactivated COVID-19 vaccine (Vero cells) regimen, were recruited in the current study. Serum IgG and IgM antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were determined by using chemiluminescent microparticle immunoassay (CMIA).
Results: There were no significant differences regarding the seroprevalences of IgG and IgM antibodies against SARS-CoV-2, and the self-reported vaccination-related adverse events among SLE patients, RA patients and HCs. The inactivated COVID-19 vaccines appeared to be well-tolerated and moderately immunogenic. In addition, case-only analysis indicated that in SLE patients, the disease manifestation of rash and anti-SSA autoantibody were associated with seroprevalence of IgG antibody against SARS-CoV-2, whereas the uses of ciclosporin and leflunomide had influence on the seroprevalence of IgM antibody against SARS-CoV-2. In RA patients, rheumatoid factor (RF) appeared to be associated with the seroprevalence of IgG antibody against SARS-CoV-2.
Conclusion: Our study reveals that the seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and vaccination-related adverse effects are similar among SLE, RA and HCs, suggesting that COVID-19 vaccine is safe and effective for SLE and RA patients to prevent from the pandemic of COVID-19.
Keywords: COVID-19; RA; SARS-CoV-2; SLE; Vaccination.
. 2022 Apr 26;150:112997.
doi: 10.1016/j.biopha.2022.112997. Online ahead of print.
Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis
Peng Wang[SUP] 1 [/SUP], Jing Ni[SUP] 2 [/SUP], Ya-Ya Chu[SUP] 3 [/SUP], Qing-Qing Chen[SUP] 4 [/SUP], Guo-Cui Wu[SUP] 5 [/SUP], Yang Fang[SUP] 6 [/SUP], Cong Chen[SUP] 6 [/SUP], Ruo-Di Zhang[SUP] 6 [/SUP], Ling-Qiong Jiang[SUP] 6 [/SUP], Yan Zhao[SUP] 6 [/SUP], Xi Fang[SUP] 6 [/SUP], Jun He[SUP] 7 [/SUP], De-Guang Wang[SUP] 8 [/SUP], Gui-Hong Wang[SUP] 9 [/SUP], Hai-Feng Pan[SUP] 10 [/SUP]
Affiliations
- PMID: 35486976
- PMCID: PMC9040458
- DOI: 10.1016/j.biopha.2022.112997
Abstract
Background: This study aimed to investigate the seroreactivity of Coronavirus disease 2019 (COVID-19) vaccination and its adverse events among systemic lupus erythematosus (SLE) patients, rheumatoid arthritis (RA) patients, and healthy controls (HCs).
Methods: A total of 60 SLE patients, 70 RA patients and 35 HCs, who received a complete inactivated COVID-19 vaccine (Vero cells) regimen, were recruited in the current study. Serum IgG and IgM antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were determined by using chemiluminescent microparticle immunoassay (CMIA).
Results: There were no significant differences regarding the seroprevalences of IgG and IgM antibodies against SARS-CoV-2, and the self-reported vaccination-related adverse events among SLE patients, RA patients and HCs. The inactivated COVID-19 vaccines appeared to be well-tolerated and moderately immunogenic. In addition, case-only analysis indicated that in SLE patients, the disease manifestation of rash and anti-SSA autoantibody were associated with seroprevalence of IgG antibody against SARS-CoV-2, whereas the uses of ciclosporin and leflunomide had influence on the seroprevalence of IgM antibody against SARS-CoV-2. In RA patients, rheumatoid factor (RF) appeared to be associated with the seroprevalence of IgG antibody against SARS-CoV-2.
Conclusion: Our study reveals that the seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and vaccination-related adverse effects are similar among SLE, RA and HCs, suggesting that COVID-19 vaccine is safe and effective for SLE and RA patients to prevent from the pandemic of COVID-19.
Keywords: COVID-19; RA; SARS-CoV-2; SLE; Vaccination.